Great Point Partners’s Ascendis Pharma A/S ASND Stock Holding History

Great Point Partners’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-75,000	Closed	-$14.9M	–	33
2025 Q3	$14.9M	Buy	+75,000	New	+$14M	6.15%	6
2025 Q2	–	Sell	-50,000	Closed	-$7.79M	–	27
2025 Q1	$7.79M	Buy	+50,000	New	+$7.14M	4.13%	9
2019 Q4	–	Sell	-300,000	Closed	-$28.9M	–	40
2019 Q3	$28.9M	Sell	300,000 -200,000	-40%	-$22.3M	2.65%	14
2019 Q2	$57.6M	Buy	500,000 +85,000	+20%	+$10.2M	6.39%	7
2019 Q1	$48.8M	Buy	+415,000	New	+$36.3M	4.83%	8
2016 Q3	–	Sell	-76,511	Closed	-$1.01M	–	39
2016 Q2	$1.01M	Buy	+76,511	New	+$1.18M	0.29%	29
2015 Q3	–	Sell	-311,222	Closed	-$5.5M	–	37
2015 Q2	$5.5M	Sell	311,222 -28,641	-8%	-$501K	2.14%	19
2015 Q1	$5.9M	Buy	+339,863	New	+$6.18M	2.59%	15

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Great Point Partners's ASND Position: Q4 2025 in Review

Great Point Partners sold out of Ascendis Pharma A/S (ASND) in Q4 2025, closing a stake of 75,000 shares — an estimated $14.9M sold.

Great Point Partners first reported a position in ASND in Q1 2015 and held it in 8 quarters. The position peaked at $57.6M in Q2 2019. 302 funds tracked by Wall St. Rank hold ASND as of Q4 2025.

Great Point Partners reported no remaining Ascendis Pharma A/S position as of Q4 2025 after selling out during the quarter.
Great Point Partners sold 75,000 Ascendis Pharma A/S shares in Q4 2025, an estimated $14.9M.
Great Point Partners first reported a position in Ascendis Pharma A/S in Q1 2015 and held it in 8 quarters.
Great Point Partners's Ascendis Pharma A/S position peaked at $57.6M in Q2 2019.
302 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2025.

Based on Great Point Partners's 13F filing for Q4 2025, filed 17 Feb 2026.